Myriad Genetic

Forecast & Rating9 analysts currently cover Myriad Genetic, with about 22.2% giving a positive rating — meaning they expect the stock to rise. The average price target is $3.77, about 17.8% upside from the current price of $3.20. Price targets range from $2.50 to $5.45 — a wide spread, showing clear disagreement over just how much Myriad Genetic can rise. Historically, about 75.7% of past price targets were eventually met, which adds credibility. For you, this means most institutions are cautious on Myriad Genetic's outlook. Data as of Aug 20, 2026; for reference only and not investment advice.